GLS1 Inhibitor Screening Kit is a plate-based fluorometric kit for screening human GLS1 inhibitors.
Fluorescent
Inhibitor compounds
Plays an important role in the regulation of glutamine catabolism. Promotes mitochondrial respiration and increases ATP generation in cells by catalyzing the synthesis of glutamate and alpha-ketoglutarate. Increases cellular anti-oxidant function via NADH and glutathione production. May play a role in preventing tumor proliferation.
GLS
GLS, L-glutaminase, L-glutamine amidohydrolase, GA, GLS2
GLS1 Inhibitor Screening Kit is a plate-based fluorometric kit for screening human GLS1 inhibitors.
GLS, L-glutaminase, L-glutamine amidohydrolase, GA, GLS2
Fluorescent
Inhibitor compounds
Microplate (12 x 8 well strips)
Blue Ice
-20°C
-20°C
-20°C
GLS1 Inhibitor Screening Kit is a plate-based fluorometric kit for screening human GLS1 inhibitors. The hydrolysis of glutamine by glutaminase forms glutamate and ammonia. Glutamate, in the presence of a developer and enzyme mix, converts a non-fluorescent probe to a fluorescent product via an enzymatic reaction. A well-known Glutaminase inhibitor - CB-839 is provided as an inhibitor control.
This kit is sensitive and is a specific assay for screening GLS1 inhibitors.
This product is manufactured by BioVision, an Abcam company and was previously called K479 Glutaminase (GLS1) Inhibitor Screening Kit (Fluorometric). K479-100 is the same size as the 100 test size of ab283389.
This supplementary information is collated from multiple sources and compiled automatically.
Glutaminase also known as GLS or GLS1 is an enzyme that catalyzes the conversion of glutamine to glutamate an important step in cellular nitrogen and energy metabolism. This enzyme weighs approximately 65 kDa and is expressed in various tissues particularly in the brain kidney and liver. Glutaminase exists in two isoforms GLS1 and GLS2 with GLS1 being the more studied due to its role in cancer metabolism.
Glutaminase plays a central role in cellular processes by facilitating the production of glutamate which is an important neurotransmitter in the brain and a precursor for the synthesis of gamma-aminobutyric acid (GABA). It is not part of a larger complex but acts independently in the mitochondrial matrix where it performs the glutaminase reaction. The activity of this enzyme is monitored closely because it affects multiple cellular functions and has implications in many diseases.
Glutaminase is instrumental in the glutaminolysis and tricarboxylic acid (TCA) cycles. These pathways are essential for cellular energy production and biosynthesis. GLS1 activity influences other proteins such as alanine transaminase (ALT) and aspartate transaminase (AST) which also play roles in amino acid metabolism and energy production. Glutaminase inhibitors have been explored as potential therapeutic agents by disrupting the glutaminolysis pathway in cancer cells leading to decreased tumor growth.
Glutaminase has a significant link to cancer and neurodegenerative diseases. In cancer GLS1 activity is often upregulated as tumor cells require increased glutamine metabolism for growth and survival making GLS1 inhibitors a target in cancer therapy. Neurodegenerative disorders such as Alzheimer's disease also show altered glutamate levels implicating glutaminase in disease progression. These disorders highlight the enzyme's potential connections with proteins like NMDA receptors in the brain where glutamate acts as a neurotransmitter affecting synaptic activity.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Enzyme kinetics in presence and absence of CB-839. Assays were performed using kit protocol
Inhibition of Glutaminase Activity. IC 50 was determined to be 43.97 ± 20.4 nM.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com